LPAR1 and metabolic dysfunction-associated steatohepatitis: To assess whether LPAR1 expression increases during the evolution of human NASH-induced liver fibrosis, we performed bulk RNA-seq of human liver samples from a cohort of biopsy-confirmed NASH patients with a range of fibrosis stages (F1–F4).